Clinuvel Pharmaceuticals (CLVLF) Price & Analysis

Compare

43 Followers

CLVLF Stock Chart & Stats

$7.23

-$0.52(-6.64%)

At close: Jan 08 4:00 PM EST

$7.23

-$0.52(-6.64%)

Day’s Range― - ―

52-Week Range$5.98 - $8.93

Previous CloseN/A

Volume151.00

Average Volume (3M)121.00

Market Cap

$354.08M

Enterprise Value$473.06M

Total Cash (Recent Filing)$233.00M

Total Debt (Recent Filing)$341.09K

Price to Earnings (P/E)15.0

Beta0.27

Next Earnings

Sep 01, 2026

EPS Estimate

0.36

Next Dividend Ex-DateN/A

Dividend Yield0.42%

Share Statistics

EPS (TTM)0.15

Shares Outstanding50,200,740

10 Day Avg. Volume205

30 Day Avg. Volume121

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.16

Price to Sales (P/S)5.47

P/FCF Ratio12.74

Enterprise Value/Market Cap1.34

Enterprise Value/Revenue4.91

Enterprise Value/Gross Profit7.71

Enterprise Value/Ebitda11.36

Forecast

1Y Price Target

$14.66

Price Target Upside102.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)0.5

Revenue Forecast (FY)$70.39M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA long-established debt-free position and a 22% increase in cash reserves provide durable financial flexibility. This supports ongoing R&D, commercial roll-out and dividend policy, reduces refinancing risk and buffers operational volatility over the next several quarters.

Consistent Profitability And MarginsSustained high margins and consecutive profitable years indicate a robust, cash-generative business model. Consistent dividend payouts reflect predictable cash conversion and management focus on shareholder returns, underpinning long-term financial stability.

Commercial Expansion And Revenue MomentumCross-border market access gains and a growing accredited site network in the U.S., plus improving reimbursement, translate to structurally larger addressable sales. Breaking $100M revenue and site rollout momentum support medium-term sustainable revenue growth.

Bears Say

Product Concentration RiskDependence on a single marketed product concentrates commercial and regulatory risk: any adverse payer decisions, safety events or competitive entrants could materially affect revenues and cash generation. Diversification remains limited over the next several quarters.

Regulatory Setback For Label ExpansionA failed adolescent expansion approval with the EMA constrains market growth and delays access to an adjacent patient cohort. Regulatory pushbacks can materially extend timelines and increase development and market-access costs, limiting near-term addressable market expansion.

Rising Operating CostsA sustained increase in operating and personnel costs can compress margins and reduce free cash flow if revenue growth slows. If higher expense run-rate persists for expansion and R&D, it will require continued cash generation or allocation trade-offs over the coming reporting periods.

Clinuvel Pharmaceuticals News

Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals reported a 4% rise in half-year revenues...

8d ago

Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings

An update from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals has issued an update noting...

1M ago

Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals has begun dosing in a new preclinical...

2M ago

Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients

The latest announcement is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has reported new clinical data...

2M ago

Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an update. Clinuvel Pharmaceuticals Limited, an Australian listed biopharmaceutical company trading...

2M ago

Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Clinuvel Pharmaceuticals has filed a draft registration statement, including...

3M ago

CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. CLINUVEL PHARMACEUTICALS LTD has announced a significant...

3M ago

CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an update. CLINUVEL Pharmaceuticals announced a significant milestone with the planned...

3M ago

Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus

The latest update is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has issued a release highlighting...

4M ago

CLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an update. CLINUVEL Pharmaceuticals announced potential delays in its plan to...

4M ago

CLVLF FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest stock price was $5.98 and its highest was $8.93 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is $354.08M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 179 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported $0.145 earnings per share for the quarter, missing the consensus estimate of $0.207 by -$0.061.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited pays a Annually dividend of $0.033 which represents an annual dividend yield of 0.42%. See more information on Clinuvel Pharmaceuticals Limited dividends here

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.36.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,200,740 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of $0.145 in its last earnings report, missing expectations of $0.207. Following the earnings report the stock price went down -6.143%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in CLVLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

15.90%

Trailing 12-Months

Asset Growth

15.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals (CLVLF) Earnings & Revenues

Historic Earnings Reports

CLVLF Company Deck

CLVLF Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth, a solid financial position, and significant progress in clinical trials, despite increased expenses and a regulatory setback. The company's expansion in the U.S. and consistent profitability were notable achievements. However, delays in revenue recognition and increased operational costs posed challenges.View all CLVLF earnings summaries

CLVLF Stock 12 Month Forecast

Average Price Target

$14.66

▲(102.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","8.75":"$8.75","12.5":"$12.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.6710066,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.663360565,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.165702,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.75,12.5,16.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.125,8.090077430769231,9.055154861538462,10.020232292307693,10.985309723076924,11.950387153846155,12.915464584615384,13.880542015384615,14.845619446153846,15.810696876923076,16.77577430769231,17.740851738461537,18.705929169230767,{"y":19.6710066,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.125,7.704873889615385,8.28474777923077,8.864621668846153,9.444495558461538,10.024369448076923,10.604243337692306,11.184117227307691,11.763991116923076,12.343865006538461,12.923738896153846,13.50361278576923,14.083486675384615,{"y":14.663360565,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.125,7.281977076923077,7.438954153846153,7.595931230769231,7.752908307692308,7.909885384615384,8.066862461538461,8.223839538461538,8.380816615384616,8.537793692307693,8.694770769230768,8.851747846153845,9.008724923076922,{"y":9.165702,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.125,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >